Monoclonal antibody therapy of cancer
GP Adams, LM Weiner - Nature biotechnology, 2005 - nature.com
The most significant recent advances in the application of monoclonal antibodies (mAbs) to
oncology have been the introduction and approval of bevacizumab (Avastin), an anti …
oncology have been the introduction and approval of bevacizumab (Avastin), an anti …
[引用][C] Monoclonal antibody therapy of cancer: Antibody engineering and manufacture
GP ADAMS, LM WEINER - Nature biotechnology, 2005 - pascal-francis.inist.fr
Monoclonal antibody therapy of cancer : Antibody engineering and manufacture CNRS Inist
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …
[引用][C] Monoclonal antibody therapy of cancer
GP Adams, LM Weiner - Nature Biotechnology, 2005 - cir.nii.ac.jp
Monoclonal antibody therapy of cancer
GP Adams, LM Weiner - Nature biotechnology, 2005 - pubmed.ncbi.nlm.nih.gov
The most significant recent advances in the application of monoclonal antibodies (mAbs) to
oncology have been the introduction and approval of bevacizumab (Avastin), an anti …
oncology have been the introduction and approval of bevacizumab (Avastin), an anti …
Monoclonal antibody therapy of cancer.
GP Adams, LM Weiner - Nature Biotechnology, 2005 - go.gale.com
A century ago, Paul Ehrlich hypothesized that a'magic bullet'could be developed to
selectively target disease. This vision became practical with the development of hybridoma …
selectively target disease. This vision became practical with the development of hybridoma …
Monoclonal antibody therapy of cancer.
GP Adams, LM Weiner - Nature Biotechnology, 2005 - search.ebscohost.com
The most significant recent advances in the application of monoclonal antibodies (mAbs) to
oncology have been the introduction and approval of bevacizumab (Avastin), an anti …
oncology have been the introduction and approval of bevacizumab (Avastin), an anti …
Monoclonal antibody therapy of cancer.
GP Adams, LM Weiner - Nature Biotechnology, 2005 - europepmc.org
The most significant recent advances in the application of monoclonal antibodies (mAbs) to
oncology have been the introduction and approval of bevacizumab (Avastin), an anti …
oncology have been the introduction and approval of bevacizumab (Avastin), an anti …